Insider Selling: Illumina, Inc. (ILMN) EVP Sells 2,000 Shares of Stock
Illumina, Inc. (NASDAQ:ILMN) EVP Marc Stapley sold 2,000 shares of the firm’s stock in a transaction dated Wednesday, November 15th. The shares were sold at an average price of $205.48, for a total value of $410,960.00. Following the completion of the sale, the executive vice president now directly owns 30,370 shares in the company, valued at $6,240,427.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Marc Stapley also recently made the following trade(s):
- On Thursday, October 26th, Marc Stapley sold 2,000 shares of Illumina stock. The stock was sold at an average price of $206.88, for a total transaction of $413,760.00.
- On Tuesday, September 5th, Marc Stapley sold 2,000 shares of Illumina stock. The stock was sold at an average price of $205.93, for a total transaction of $411,860.00.
Shares of Illumina, Inc. (NASDAQ:ILMN) traded up $3.09 on Thursday, hitting $208.51. 563,729 shares of the stock were exchanged, compared to its average volume of 961,646. The company has a market cap of $30,440.00, a price-to-earnings ratio of 60.25, a price-to-earnings-growth ratio of 3.40 and a beta of 0.74. The company has a current ratio of 4.22, a quick ratio of 3.73 and a debt-to-equity ratio of 0.41. Illumina, Inc. has a 1 year low of $119.37 and a 1 year high of $214.50.
Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Tuesday, October 24th. The life sciences company reported $1.11 EPS for the quarter, beating the Zacks’ consensus estimate of $0.99 by $0.12. The company had revenue of $714.00 million during the quarter, compared to analyst estimates of $692.77 million. Illumina had a net margin of 30.34% and a return on equity of 19.42%. The firm’s revenue was up 17.6% compared to the same quarter last year. During the same period in the prior year, the business posted $0.97 EPS. equities research analysts forecast that Illumina, Inc. will post 3.75 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “Insider Selling: Illumina, Inc. (ILMN) EVP Sells 2,000 Shares of Stock” was originally reported by American Banking News and is the property of of American Banking News. If you are reading this article on another website, it was copied illegally and republished in violation of U.S. and international copyright legislation. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/11/16/insider-selling-illumina-inc-ilmn-evp-sells-2000-shares-of-stock-2.html.
Institutional investors have recently modified their holdings of the business. Winslow Capital Management LLC purchased a new stake in Illumina during the 2nd quarter valued at about $211,584,000. HPM Partners LLC lifted its stake in Illumina by 29,103.8% during the 2nd quarter. HPM Partners LLC now owns 751,999 shares of the life sciences company’s stock valued at $107,724,000 after acquiring an additional 749,424 shares during the period. Fred Alger Management Inc. lifted its stake in shares of Illumina by 611.9% in the 2nd quarter. Fred Alger Management Inc. now owns 637,597 shares of the life sciences company’s stock worth $110,636,000 after purchasing an additional 548,030 shares during the period. TIAA CREF Investment Management LLC lifted its stake in shares of Illumina by 55.6% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 1,475,669 shares of the life sciences company’s stock worth $256,058,000 after purchasing an additional 527,548 shares during the period. Finally, Capital World Investors lifted its stake in shares of Illumina by 23.8% in the 2nd quarter. Capital World Investors now owns 2,135,000 shares of the life sciences company’s stock worth $370,465,000 after purchasing an additional 410,000 shares during the period. 92.70% of the stock is currently owned by institutional investors and hedge funds.
A number of brokerages recently weighed in on ILMN. BidaskClub lowered shares of Illumina from a “hold” rating to a “sell” rating in a report on Thursday, August 17th. Zacks Investment Research downgraded shares of Illumina from a “buy” rating to a “hold” rating in a research note on Friday, August 4th. J P Morgan Chase & Co reissued an “overweight” rating and issued a $250.00 price objective on shares of Illumina in a research note on Wednesday, August 2nd. Canaccord Genuity reissued a “buy” rating and issued a $230.00 price objective (up previously from $215.00) on shares of Illumina in a research note on Thursday, October 12th. Finally, Goldman Sachs Group, Inc. (The) reissued a “neutral” rating and issued a $200.00 price objective on shares of Illumina in a research note on Tuesday, September 26th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and thirteen have assigned a buy rating to the stock. Illumina presently has an average rating of “Hold” and a consensus target price of $200.88.
Illumina Company Profile
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.